We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Baxter Recalls More Products Due to Particulates

Baxter Recalls More Products Due to Particulates

August 22, 2014

Baxter continues to be plagued with particulate problems, recalling two lots of a dialysis solution and a lot of saline solution that is currently in short supply.

The drugmaker said it is voluntarily recalling two lots of dianeal low calcium peritoneal dialysis solution with 2.5 percent dextrose 5000 ml. The FDA issued an alert the same day regarding the recall of a single lot of the saline solution, 0.9 percent sodium chloride injection, USP 1000 ml.  Both recalls are linked to particulates.

The sodium chloride recall was triggered by unidentified particulate matter found near the administration port. The two lots of dialysis solution were recalled after oxidized stainless steel, garment fiber and polyvinyl chloride particulates were identified during the manufacturing process.

Baxter did not elaborate on the specific cause of the particulates or what it did to resolve the issues.

The drugmaker has not received any adverse events related to the recalled products, but health risks — such as blocked blood vessels — are of concern with administration of a product containing particulates.

With the dialysis solution, particulate matter could create a focal point for infection if any pre-existing peritonitis exists, possibly resulting in death, Baxter said.

The recalls come one month after Baxter pulled four lots of intravenous solution off the shelves due to complaints of plastic and fiber particles.

The recall of 0.9 percent sodium chloride injection comes in the midst of an ongoing saline shortage first reported in January. In April, Baxter agreed to temporarily distribute saline in the U.S. from its Spain manufacturing facility to help boost supplies, according to the FDA.

Baxter did not return a request for comment by press time.

Make sure your products are particulate free! Avoid a warning letter and ensure that you’re producing sterile products, order Manufacturing Sterile Products to Meet EU and FDA Guidelines today!

Pharmaceuticals Postmarket Safety Commercial Operations

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

  • 10Feb

    FDA Under the Biden Administration: What’s to Come and What It Will Mean

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • CE mark

    MiRXES Earns CE Mark for COVID-19/Flu Test

  • KitePharma_Logo

    Kite Pharma’s Tecartus Gains UK Recommendation for Lymphoma

  • Eli Lilly logo

    Lilly’s Monoclonal Antibody Could Prevent COVID-19 in the Elderly

  • CE mark

    Fluidigm Gains CE Mark for Saliva-Based Assay for COVID-19

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing